UBS Group AG Boosts Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

UBS Group AG boosted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 22.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 668,811 shares of the biopharmaceutical company’s stock after acquiring an additional 121,786 shares during the quarter. UBS Group AG’s holdings in Ultragenyx Pharmaceutical were worth $15,383,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Assetmark Inc. raised its position in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares in the last quarter. Huntington National Bank raised its position in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S bought a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at $39,000. Smartleaf Asset Management LLC raised its position in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares in the last quarter. Finally, Covestor Ltd raised its position in Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate for Ultragenyx, suggesting a slightly better outlook for that period. Ultragenyx Pharmaceutical analyst estimate update
• Neutral Sentiment: The company presented at the Bank of America Global Healthcare Conference 2026, which appears to be a routine investor-relations event rather than a major catalyst. Ultragenyx Pharmaceutical conference transcript
• Negative Sentiment: HC Wainwright trimmed Q1 2027, Q2 2027, Q3 2027, FY2026, and FY2027 EPS estimates slightly, reinforcing ongoing pressure on earnings expectations. Ultragenyx Pharmaceutical earnings estimate reductions
• Negative Sentiment: Near-term earnings expectations remain deeply negative, with HC Wainwright still projecting losses and full-year 2026 EPS below the broader consensus, which can weigh on sentiment. Ultragenyx Pharmaceutical earnings outlook

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Erik Harris sold 10,539 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $240,289.20. Following the completion of the transaction, the executive vice president directly owned 89,515 shares of the company’s stock, valued at approximately $2,040,942. The trade was a 10.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emil D. Kakkis sold 54,404 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the transaction, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at approximately $15,025,063.20. The trade was a 7.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 111,522 shares of company stock worth $2,543,214. Company insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on RARE shares. Truist Financial raised Ultragenyx Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. HC Wainwright decreased their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Wedbush decreased their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Morgan Stanley lifted their target price on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, April 16th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.41.

Ultragenyx Pharmaceutical Trading Down 1.4%

RARE opened at $26.46 on Thursday. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of -4.33 and a beta of 0.39. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37. The stock has a fifty day moving average price of $22.95 and a 200-day moving average price of $26.59.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company’s revenue was down 2.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.57) earnings per share. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.63 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.